CW January 2006
Volume 15Issue Number 1 January 2006 ISSN 10593802 Campath Works in ?Real-Life? CLL, Improves with Continuous IVStudies of alemtuzumab (Campath, Berlex) in previously treated patients with chronic lymphocytic leukemia (CLL) show the agent to be effective in routine ?real-life? settings, and show further that giving the agent through a continuous intravenous infusion may improve complete response (CR) rates.
Go to Previous Page Go to Next Page Source & Additional Reading Lundin J et al., Blood 100, 768-773, 2002. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
